Epidemiological and Entomological Evaluations after Six Years or More of Mass Drug Administration for Lymphatic Filariasis Elimination in Nigeria

F ank O. Richa d¹, Abel Eigege², Emman el S. Mi i², Al hen Kal², Jehn Uma², Da e Pam³, Lind a J. Rake^{1*}, Yehanna Sambe², Jaceb Danbe i⁵, Bake Ib ahim³, Selemen E. Adelame², Glad Ogah⁵, Danj ma Ge hi⁴, O. Kehinde O enekan², El Ma hie⁷, P. C aig Wi he¹, Yi a A. Saka⁶, Jena han Ji a⁶, Denald R. He kin¹

1 The Carter Center, Atlanta, Georgia, United States of America, 2 The Carter Center, Jos, Nigeria, 3 University of Jos, Plateau State, Jos, Nigeria, 4 Plateau State Ministry of Health, Jos, Nigeria, 5 Nasarawa State Ministry of Health, Lafia, Nigeria, 6 Nigeria Federal Ministry of Health, Abuja, Nigeria, 7 Centers for Disease Control, Atlanta, Georgia, United States of America

Ab ac

The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at


e el spill 1.00 17 1992 •1 30 17 A 23,24,2 1992 T c 91 . 12 🖪 A 9 1993 600,000 🐉 🕹 23,24**.** A 11 14 ₹_¥ 91 1997 101 Y /1 1 26 9 ð 6 ۶, 9] 1 А ,**"**1 9 ъ 1998 1999. ٩ h 11 91 • 7**0** A 7 6 ст.^{9]} A 27,28,. م به الله من مع الم من م م م مالك الم م م م 5. Ol r 11


LF Mapping

1998 2000 2. 14 ,•1 % çД Ŕ c ۹ ، e. . 1,, 1, r ²⁹ 1998 J ,•! •! 9 5.2 ð. 2 149 ≥15 4,451 n ¢ er c 12.9% Ar c 10% و 26,30 œ 17 .1 1 .1 J. 1. . ••• Α., ť ī.

1999 2000 5 2 12 3 č, q 2.0 6 Я 30 2 : 1 5,211 50 100 19 • (100)170 Ģ A 2 08540) 9 ٩. c] <u>و</u>. وا 1 j9 ٧, 1, ۹ ا k 17 6.0 11 - 1 4 11 , A 11 6 ₽ Ą 3 · 1 · 1 ٩٩] * €>1%, . . , . 1.1 e Van · • • (Je) А Я Я $(\mathbf{e}^{\dagger}\mathbf{e}^{\dagger} - \mathbf{e}^{\dagger}\mathbf{r} - \mathbf{r}^{\dagger})$ P A 4

Mass Drug Administration





: www.plosntds.org

Entomology

Sen inel

Table 1. Annual reported treatment coverage of eligible population of sentinel villages, and 2003 surveyed coverage.

چې تولو الالا، دې مالا د اوم 90% لام لو د کول د د لاو بولا چې کو ار مالا.

Surveillance for Adverse Events (2001 2003) J. C. 0.41 1.16%, J. (0.10

Table 2.








Fig e 5. Mean en inel illage an igen e alence b MDA ea men ea (n = 9,394). Filarial antigenemia as determined by ICT testing. SV results across all four MDA phases have been adjusted to MDA treatment year for comparability. Data for the baseline antigen for five villages (Gbuwhen, Gwamlar, Lankan, Maiganga, and Seri) were from 1999–2000 mapping surveys. Baseline for the remaining villages (Akwete, Anzara, Babale, Dokan Tofa, Piapung) combined values from the community wide nocturnal pre-treatment surveys conducted in 2003 with pre-treatment data from the 1999–2000 mapping surveys. Chi square for trend not significant (p = 0.06 for all MDA years and p = 0.271 for baseline through MDA year 6). Bars show 95% confidence intervals. doi:10.1371/journal.pntd.0001346.g005





Table 4.



Dic i●n




Fig e 7. Age- ecific e alence fo mf o LF an igen in Dokan Tofa and Pia ng en inel illage . Panel A: Dokan Tofa pretreatment prevalence by age group (n = 418). Panel B: Piapung pretreatment prevalence by age group (n = 400). Panel C: Dokan Tofa prevalence by age group after 6 rounds of MDA (n = 223). Panel D: Piapung prevalence by age group after 6 rounds of MDA (n = 280). Boxes show numbers sampled in each age group. Pretreatment sample for mf is different from Table 2 because ages were not available on all persons tested. Pretreatment sample for antigen for these SVs are different than baseline figure shown in Table 3 because 1999/2000 mapping data were added to baseline calculation in Table 3 (see Methods). doi:10.1371/journal.pntd.0001346.g007



Ackne ledgmen

- د المربع الم 1916 مربع المربع الم

- 155 164. 29. (2007), (2007), (2007), (2003),

- 38
 1
 , 1
 , A
 , 1
 , (2003)

 38
 1
 , 1
 , 2
 , 1
 , 1
 , 1
 , 1

 1
 , 1
 , 1
 , 1
 , 1
 , 1
 , 1
 , 1
 , 1

 2000. A
 68: 568: 573.
 39. 7.1
 A
 , 68: 568: 573.
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
 , 1.1
- 41. **3**67: 992 999.

- 70: 63 71. 48. 41. (2010) (1, 2)49. (2002) (1, 1) (1, 2) (2010) (1, 2) (2002) (1, 1) (1, 2) (1, 2) (201) (1, 2) (2002) (1, 1) (1, 2) (1, 2) (1, 2) (201) (1, 2) (2002) (1, 1) (1, 2) (1, 2) (201) (1, 2) (200) (1, 2) (2002) (1, 1) (1, 2) (2003) (1, 2) (2003) (1, 2) (2003)